Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Alert me
Pfizer Inc. 8-K filed May 5, 2026
2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.